170 related articles for article (PubMed ID: 16622453)
1. High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
de Jonge ME; Huitema AD; Beijnen JH; Rodenhuis S
Br J Cancer; 2006 May; 94(9):1226-30. PubMed ID: 16622453
[TBL] [Abstract][Full Text] [Related]
2. Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Huitema AD; Spaander M; Mathĵt RA; Tibben MM; Holtkamp MJ; Beijnen JH; Rodenhuis S
Ann Oncol; 2002 Mar; 13(3):374-84. PubMed ID: 11996467
[TBL] [Abstract][Full Text] [Related]
3. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
de Jonge ME; Huitema AD; van Dam SM; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Dec; 27(6):756-65. PubMed ID: 16306851
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
de Jonge ME; Huitema AD; Holtkamp MJ; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 Oct; 56(4):370-8. PubMed ID: 15838656
[TBL] [Abstract][Full Text] [Related]
6. Feasibility of multiple courses of high-dose cyclophosphamide, thiotepa, and carboplatin for breast cancer or germ cell cancer.
Rodenhuis S; Westermann A; Holtkamp MJ; Nooijen WJ; Baars JW; van der Wall E; Slaper-Cortenbach IC; Schornagel JH
J Clin Oncol; 1996 May; 14(5):1473-83. PubMed ID: 8622061
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Ekhart C; Rodenhuis S; Beijnen JH; Huitema AD
Ther Drug Monit; 2009 Feb; 31(1):95-103. PubMed ID: 19155964
[TBL] [Abstract][Full Text] [Related]
8. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome.
Lee JL; Gooley T; Bensinger W; Schiffman K; McDonald GB
Biol Blood Marrow Transplant; 1999; 5(5):306-15. PubMed ID: 10534061
[TBL] [Abstract][Full Text] [Related]
9. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
[TBL] [Abstract][Full Text] [Related]
10. Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
de Jonge ME; Huitema AD; Rodenhuis S; Beijnen JH
Ther Drug Monit; 2005 Jun; 27(3):393-402. PubMed ID: 15905813
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide and 4-Hydroxycyclophosphamide/aldophosphamide kinetics in patients receiving high-dose cyclophosphamide chemotherapy.
Anderson LW; Chen TL; Colvin OM; Grochow LB; Collins JM; Kennedy MJ; Strong JM
Clin Cancer Res; 1996 Sep; 2(9):1481-7. PubMed ID: 9816324
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Schrama JG; Baars JW; Holtkamp MJ; Schornagel JH; Beijnen JH; Rodenhuis S
Bone Marrow Transplant; 2001 Jul; 28(2):173-80. PubMed ID: 11509935
[TBL] [Abstract][Full Text] [Related]
13. Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation.
Chen TL; Kennedy MJ; Anderson LW; Kiraly SB; Black KC; Colvin OM; Grochow LB
Drug Metab Dispos; 1997 May; 25(5):544-51. PubMed ID: 9152592
[TBL] [Abstract][Full Text] [Related]
14. Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
de Jonge ME; Huitema AD; van Dam SM; Beijnen JH; Rodenhuis S
Cancer Chemother Pharmacol; 2005 May; 55(5):507-10. PubMed ID: 15685452
[TBL] [Abstract][Full Text] [Related]
15. Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
de Jonge ME; Mathôt RA; Dalesio O; Huitema AD; Rodenhuis S; Beijnen JH
Bone Marrow Transplant; 2002 Nov; 30(9):593-7. PubMed ID: 12407434
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
[TBL] [Abstract][Full Text] [Related]
17. Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
Huitema AD; Kerbusch T; Tibben MM; Rodenhuis S; Beijnen JH
Cancer Chemother Pharmacol; 2000; 46(2):119-27. PubMed ID: 10972481
[TBL] [Abstract][Full Text] [Related]
18. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation.
McDonald GB; Slattery JT; Bouvier ME; Ren S; Batchelder AL; Kalhorn TF; Schoch HG; Anasetti C; Gooley T
Blood; 2003 Mar; 101(5):2043-8. PubMed ID: 12406916
[TBL] [Abstract][Full Text] [Related]
19. A multi-center prospective phase II study of high-dose chemotherapy in germ-cell cancer patients relapsing from complete remission.
Rodenhuis S; de Wit R; de Mulder PH; Keizer HJ; Sleijfer DT; Lalisang RI; Bakker PJ; Mandjes I; Kooi M; de Vries EG
Ann Oncol; 1999 Dec; 10(12):1467-73. PubMed ID: 10643538
[TBL] [Abstract][Full Text] [Related]
20. In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa).
Bouligand J; Boland I; Valteau-Couanet D; Deroussent A; Kalifa C; Hartmann O; Vassal G
Bone Marrow Transplant; 2003 Nov; 32(10):979-86. PubMed ID: 14595385
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
